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Abstract
Purpose The aim of this study was to investigate whether
associating liver partition and portal vein ligation for staged
hepatectomy (ALPPS) can be used as an effective and safe
rescue procedure in patients with colorectal liver metastases
(CRLM) and insufficient effect on the future liver remnant
(FLR) after previous portal vein occlusion (PVO).
Methods Eleven patients with bilobar CRLM treated with
neoadjuvant chemotherapy and previous PVO with insuffi-
cient effect on the FLR were analyzed retrospectively from a
prospective database. FLR was evaluated with computed to-
mography volumetry 6 days after stage 1, and stage 2 was
performed on day seven.
Results Six days after stage 1, the median increase of the FLR
was 209ml (range 87–314,P < 0.001). This corresponded to a
median FLR growth of 61.8 % (range 19.3–120) resulting in
an FLR/BW ratio >0.5 % in all patients and successful subse-
quent removal of the tumor bearing liver (segments IV–VIII)
in all patients with no 90-day mortality. No patient had a 3b-
complication or more according to Clavien-Dindo. No patient
developed severe posthepatectomy liver failure.
Conclusions The powerful hypertrophy of the FLR associated
with ALPPS seems to be maintained in patients with CRLM
and previous failed PVO.
Keywords Liver resection . Colorectal liver metastases .
ALPPS . PVO
Introduction
Portal vein occlusion (PVO) by either selective embolization
(PVE) or ligation (PVL) of the portal vein to the tumor bearing
part of the liver is an established method to increase the size of
the future liver remnant (FLR) [1, 2]. The main purpose of this
procedure is to convert previously unresectable patients to
resection candidates by achieving sufficient size of the FLR
before hepatectomy, in order to avoid posthepatectomy liver
failure (PHLF) [3].
However, it has to be recalled that about one third of
the patients submitted to PVO eventually never undergo a
curative resection due to either insufficient growth of the
FLR with an unacceptable risk of PHLF if submitted to
surgery, or they progress to an unresectable local tumor
situation while awaiting the full PVO effect [4, 5].
Associating liver partition and portal vein ligation for staged
hepatectomy (ALPPS) has rendered great attention since its in-
troduction [6, 7]. Although showing promising results with un-
precedented growth of FLR, both in time and size, the technique
has also been subjected to criticism, mainly because of high
morbidity and mortality rates [8, 9]. A recent review of the liter-
ature shows that the majority of the serious complications affect
patients subjected to concomitant biliary surgery [6, 10, 11],
while patients with colorectal liver metastases (CRLM) undergo-
ing ALPPS seem to be less prone to develop high-grade compli-
cations [11]. In an attempt to address patients with insufficient
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growth of the FLR after PVO, a modified ALPPS with only
parenchymal transection (Brescue^ ALPPS) has been reported
in a few small case series [12–15].
The aim of this study was to investigate whether ALPPS
can be used as an effective and safe rescue procedure in pa-




FromNovember 2012 to June 2015, 11 patients were included in
the study from a prospective database at the Center for Digestive
Diseases at Karolinska University Hospital. All patients present-
ed with bilobar CRLM and had been treated with neoadjuvant
chemotherapy. The patients were previously subjected to PVO
(PVE, PVL, or both) with insufficient effect on the FLR and
subsequently operated with rescue ALPPS. All patients were
discussed at the local MDT conference. A ratio between FLR
and body weight (FLR/BW ratio) of less than 0.5 %was consid-
ered as an indication for ALPPS [16]. Six days after stage 1, FLR
was evaluated with computed tomography (CT) volumetry and
stage 2 was performed on day seven. All patients had bilobar
tumor manifestation but only four had metastases in segment I,
II, or III requiring tumor clearance of the FLR at stage 1 (the
remaining hadmetastases in segment IVin addition to the tumors
in the right liver lobe). All patients were treated with neoadjuvant
chemotherapy with a median of seven cycles (range 4–14). The
treatment agents consisted of FOLFOX or FOLFIRI +/− a bio-
logical agent. The time elapsed from completion of chemothera-
py treatment to stage 1 operation in the study was in median
85 days (range 26–172), as a result of the waiting time from
PVO to ALPPS given the fact that chemotherapy was not given
after PVO. The clinicopathological characteristics of the patient
cohort are presented in detail in Table 1.
Surgical technique
PVE was performed with percutaneous ipsilateral technique
and puncture of peripheral portal branches of the right side.
Polyvinyl alcohol beads (Terumo Bead Block™ Embolic
Bead, Metron Healthcare, Athens, Greece) and polyvinyl al-
cohol particles (Contour™, Boston Scientic, Cork, Ireland)
were combined with central coils (MicroNester®
Embolization Coil, Cook, Indianapolis, USA), placed in the
right portal vein, to obtain occlusion of the portovenous sys-
tem to segment V–VIII. The portal branches to segment IV
were not embolized as this is not routine at our center. PVL
was performed by division of the right portal vein using a
stapler instrument (Endo GIA™ Universal with Tri-
Staple™, Covidien, Dublin, Ireland). PVL was preferred over
PVE only when the FLR contained metastases and used to-
gether with local resections in FLR in the stage 1 operation of
an intended conventional two-stage hepatectomy. ALPPS was
performed in a similar way as described previously [6] in the
patients with failed PVE. In summary, stage 1 comprised of
division of the right portal vein as in PVL and complete pa-
renchymal transection to the right of the falciform ligament
using cavitron ultrasonic surgical aspirator (CUSA®,
Valleylab Inc., Boulder, CO, USA). In rescue ALPPS after
failed PVL, only parenchymal transection was performed at
stage 1. At stage 2, performed 7 days later in all patients, the
right portal pedicle and right liver vein were divided using the
same stapler instrument as above and the tumor bearing
deportalized liver could be removed as in an extended right-
sided hemihepatectomy preserving only segment I–III in all
patients.
Volumetric analysis
Liver volume was calculated from a four-phase contrast en-
hanced CT of the liver by using the software Volume Viewer©
(Voxtool 11.x) for AW Volume Share 5 implemented on an AW
Workstation (GE Healthcare, Fairfield, CT, USA). The CT eval-
uating the effect of the PVO was performed after 28 days in
median (range 19–33) and was used as baseline investigation
(Table 1). To measure the effect on the FLR, all patients
underwent a second CT of the liver on day six after stage 1
(Fig. 1). The FLR/BW ratio was calculated and total estimated
liver volume (TELV) was calculated according to the formula
developed by Vauthey and co-workers to obtain standardized
FLR (sFLR) [17].
Data collection and statistical analysis
Baseline patient characteristics, volumetric data, procedural
data, and complications were collected prospectively in a local
database. Statistical analysis was performed using JMP® ver-
sion 5.1 (SAS Institute Inc., Cary, NC, USA). Median values
(range) were used for continuous variables whereas frequen-
cies were calculated for categorical variables. Paired t test was
used to compare means between different time points in the
same patient. P values of <0.05 were considered to represent
statistical significance.
The study protocol was approved by the Central Ethical
Review Board, Stockholm, Sweden.
Results
Clinical outcome
The median operating time for stage 1 was 282 min (range
200–398) with an intraoperative blood loss of 1500 ml (range
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400–5600). In the four patients requiring tumor clearance
of the FLR, local resections were performed in two pa-
tients, and in two patients, a combination of local resec-
tions and microwave ablation (MWA) was used. All these
procedures for metastases in the FLR were undertaken
during the stage 1 procedure. All patients could complete
stage 2 with the removal of the tumor bear ing
deportalized liver. Radical resection (R0) was achieved
in all 11 patients. The complication rate was low. Four
patients had pleural effusion that was drained in local
anesthesia, consequently recorded as a 3a-complication
according to the Clavien-Dindo classification [18, 19].
In one patient, this occurred after stage 1 and in the re-
maining three after stage 2. There were no complications
equal to or above 3b. No patient fulfilled the Balzan 50/50
[20], peak bilirubin >7 [21], or ISGLS [22] criteria grade
C for severe postoperative liver failure and there was no
90-day mortality. Detailed postoperative clinical data are
shown in Table 2.
Fig. 1 Example of rescue ALPPS after failed portal vein embolization
CT after PVE (a) and CT before stage 2 (b) in the same patient
Table 1 Clinicopathological
characteristics of the patient
cohort (n = 11) before ALPPS
Variable Rescue ALPPS (n = 11)
Median age, years (range) 67 (41–74)
Male/female gender 8/3




Median number of liver metastases (range) 7 (2–20)
Tumor localization
Right lobe + segment 4 7





Number of chemotherapy cycles (range) 7 (4–14)
Days between chemo and ALPPS (range) 85 (26–172)
Portal vein occlusion prior to ALPPS
Portal vein embolization (PVE) 5
Portal vein ligation (PVL) 4
First PVL then PVE 2
TELV, ml (range) 1651 (1436–2070)
FLR before PVO, ml (range) 250 (180–370)
FLR/BW ratio before PVO, % (range) 0.33 (0.25–0.40)
sFLR before PVO, % (range) 14.9 (11.9–19.7)
Growth of FLR after PVO, % (range) 26.8 (−7.3–66.7)
Days from PVO to CT 28 (19–33)
FLR before ALPPS, ml (range) 312 (260–450)
FLR/BW ratio before ALPPS, % (range) 0.41 (0.35–0.49)
sFLR before ALPPS, % (range) 18.7 (16.1–23.8)
ASA American Society of Anesthesiologists Physical Classification System, TELV total estimated liver volume,
FLR future liver remnant, sFLR standardized FLR, FLR/BW ratio FLR to body weight ratio
Langenbecks Arch Surg (2017) 402:69–75 71
Growth of the FLR
FLR volume before PVO was 250 ml (range 180–370).
After PVO the FLR increased to 312 ml (range 260–
450), representing a growth of the FLR with 26.8 %
(range − 7.3-66.7, P = 0.006). All patients responded well
to the ALPPS stage 1 procedure despite previous PVO. Six
days after stage 1, the median increase of the FLR was
209 ml (range 87–314, P < 0.001). This corresponded to
an increase of FLR/BW ratio to 0.69 % (range 0.59–0.81),
i.e., reaching more than 0.5 % in all patients (Fig. 2a). In
Fig. 2b, the corresponding increase in sFLR is also present-
ed. The growth of the FLR between stage 1 and 2 was in
median 61.8 % (range 19.3–120). For further details regard-
ing volumetrical data, see Tables 1 and 2.
Discussion
This study confirms results from previous smaller case reports
that ALPPS can be both safe and effective as a rescue proce-
dure in CRLM patients with insufficient effect on the FLR
after previous PVO. In addition, it seems as if the previously
described high morbidity and mortality associated with
ALPPS does not apply when performing the procedure in this
patient group.
As mentioned, rescue ALPPS for CRLM has been de-
scribed previously [12–15], although in only quite few
patients. Despite the limited number of patients enrolled,
the patient cohort of this study still represents the largest
series of rescue ALPPS for CRLM so far presented, and
in addition, the main aim of this study was to specifically
investigate rescue ALPPS. In one recent study [15], nine
patients with ALPPS after PVE were reported but without
stating the background diagnosis and chemotherapy regi-
mens in those subjected to PVE before ALPPS. Some of
the patients in the present study were also included in a
Scandinavian multicenter study recently published [23].
However, this study also reported a mixed study popula-
tion and did not have the aim to study rescue ALPPS. To
analyze the effect and consequences of a complex proce-
dure such as ALPPS, we considered it as an advantage to
have a patient population as homogenous as possible to
minimize the effects of a variety of confounding factors.
Accordingly, we only included patients with bilobar
CRLM; all of them subjected to neoadjuvant chemother-
apy and with an FLR consisting of segment I–III in all
patients.
In the present study cohort, the overall median growth
of the FLR before stage 2 was 61.8 %, which is less than
reported in most previous studies. This might, however,
be explained by two factors. Firstly, in contrast to the
majority of other reports on ALPPS, only patients with
CRLM treated with pre-procedural chemotherapy were
included. It is recognized that pre-PVE chemotherapy
can have a negative effect on growth of the FLR after
PVE [24, 25] and it is likely to have the same effect after
ALPPS, although this remains to be proven. Another
Table 2 Procedural, clinical, and
volumetrical data after completed
ALPPS
Variable Rescue ALPPS (n = 11)
Operating time stage 1, min (range) 282 (200–398)
Bleeding during stage 1, ml (range) 1500 (400–5600)
Completed stage 2 11
R0-resection 11
Complication (Clavien-Dindo) 3a 4
Complication (Clavien-Dindo) ≥3b 0
Fulfills Balzan criteria 0
90-day mortality 0
FLR after stage 2, ml (range) 557 (395–619)
FLR/BW ratio before stage 2, % (range) 0.69 (0.59–0.81)
sFLR before stage 2, % (range) 31.2 (27.5–36)
Growth of FLR between stage 1 and 2, % (range) 61.8 (19.3–120)
PK (INR) 1 day before stage 1 1.0 (0.9–1.1)
PK (INR) 5 days after stage 1 1.2 (1.1–1.5)
PK (INR) 5 days after stage 2 1.3 (1.2–1.8)
Bilirubin 1 day before stage 1 6 (3–14)
Bilirubin 5 days after stage 1 8 (6–22)
Bilirubin 5 days after stage 2 17 (8–49)
R0-resection radical resection with >1 mm margin, PK (INR) normal if <1.2, Bilirubin normal if <26 micromol/l
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complicating factor was that the interval between the ces-
sation of chemotherapy and ALPPS was quite long due to
the waiting time from PVO to ALPPS. Consequently, the
alleged negative effect of pre-procedural chemotherapy on
FLR hypertrophy might have been less pronounced in
these patients compared to the patients undergoing
ALPPS without previous PVO. Secondly, the inter-stage
time of 7 days used for all patients in this study was
shorter than in the most published series [26]. That might
in part explain the somewhat less pronounced hypertrophy
rate. Also, the volume increase of the FLR seems to be
paired with a functional increase since no patient devel-
oped severe liver failure after stage 2. This absence of
severe PHLF was seen despite the fact that a FLR/BW
ratio below 0.5 % was used for inclusion, compared to
other centers that use a FLR/BW ratio below 0.8 % or a
sFLR below 30 % for deciding to perform ALPPS in
patients with pre-procedural chemotherapy [27, 28]. In a
recent retrospective study at our institution comparing dif-
ferent volumetric methods for characterizing the size of
the FLR before and after PVE, an FLR/BW ratio of
0.5 % corresponded to a sFLR of 22.9 % and thus clearly
below sFLR of 30 % (unpublished data).
The observed low morbidity and zero mortality are
probably attributed to the inclusion of only patients with
CRLM as mentioned above. In the first publication from
the ALPPS Registry, age above 60 years was reported as
a risk factor for mortality after ALPPS in CRLM [11].
The median age in this study population was 67 years,
but we speculate that our low patient co-morbidity might
have contributed to the absence of 90-day mortality. The
resection rate in this study was 100 %, similar or higher
to what has been achieved in previous studies, which
clearly surpasses the resection rate after PVO and two-
stage hepatectomy [29]. A potential confounder might be
that some patients subjected to PVO will experience tumor
progression while waiting for the effect of the PVO ex-
cluding them from subsequent surgery, thus leading to a
possible selection bias with a more favorable tumor situa-
tion for patients undergoing rescue ALPPS compared to
those submitted directly to standard ALPPS.
The question whether ALPPS should be used more
frequently in patients with CRLM and a small FLR
remains to be answered. In this study, ALPPS was used
successfully as a rescue method after failed PVO.
Considering the potent growth of the FLR after
ALPPS, patients with CRLM and very small FLR and/
or monosegment FLR should probably be considered for
ALPPS upfront [30].
Conclusion
The powerful FLR growth associated with ALPPS
seems to remain even when performed in patients with
previous PVO. Apparently, in patients with colorectal
liver metastases subjected to previous PVO, ALPPS
can be performed with low morbidity and high resection
rate.
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